FY2025 Earnings Estimate for Neogen Issued By Zacks Research

Neogen Co. (NASDAQ:NEOG) – Analysts at Zacks Research reduced their FY2025 earnings per share estimates for Neogen in a report released on Wednesday, February 12th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.38 per share for the year, down from their prior estimate of $0.39. The consensus estimate for Neogen’s current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen’s FY2026 earnings at $0.50 EPS and FY2027 earnings at $0.57 EPS.

Neogen (NASDAQ:NEOG) last released its quarterly earnings data on Friday, January 10th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.12. The company had revenue of $231.30 million for the quarter, compared to analyst estimates of $227.16 million. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. The firm’s revenue for the quarter was up .7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.11 earnings per share.

Several other equities analysts have also commented on NEOG. Piper Sandler reaffirmed a “neutral” rating and issued a $13.00 price target (down previously from $16.50) on shares of Neogen in a research note on Tuesday, January 21st. Guggenheim began coverage on Neogen in a research note on Thursday, December 19th. They issued a “buy” rating and a $15.00 price target on the stock.

Neogen Stock Performance

NASDAQ NEOG opened at $9.92 on Friday. The stock’s fifty day moving average is $11.84 and its two-hundred day moving average is $14.26. The firm has a market capitalization of $2.15 billion, a P/E ratio of -4.53 and a beta of 1.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.46 and a current ratio of 3.77. Neogen has a fifty-two week low of $9.88 and a fifty-two week high of $18.58.

Institutional Investors Weigh In On Neogen

Several institutional investors and hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC raised its holdings in shares of Neogen by 247.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 21,086 shares of the company’s stock valued at $256,000 after buying an additional 15,022 shares during the period. MetLife Investment Management LLC raised its holdings in shares of Neogen by 7.8% in the 4th quarter. MetLife Investment Management LLC now owns 241,136 shares of the company’s stock valued at $2,927,000 after buying an additional 17,499 shares during the period. Curi RMB Capital LLC raised its holdings in shares of Neogen by 0.9% in the 4th quarter. Curi RMB Capital LLC now owns 425,063 shares of the company’s stock valued at $5,160,000 after buying an additional 3,819 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Neogen by 24.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 6,939,984 shares of the company’s stock valued at $84,254,000 after buying an additional 1,345,056 shares during the period. Finally, Gamco Investors INC. ET AL raised its holdings in shares of Neogen by 9.9% in the 4th quarter. Gamco Investors INC. ET AL now owns 62,130 shares of the company’s stock valued at $754,000 after buying an additional 5,600 shares during the period. Hedge funds and other institutional investors own 96.73% of the company’s stock.

Insider Activity

In other Neogen news, CFO David H. Naemura purchased 14,800 shares of the firm’s stock in a transaction dated Thursday, January 16th. The shares were acquired at an average price of $11.11 per share, with a total value of $164,428.00. Following the purchase, the chief financial officer now directly owns 61,434 shares in the company, valued at approximately $682,531.74. This trade represents a 31.74 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO John Edward Adent acquired 23,035 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The stock was purchased at an average price of $11.03 per share, for a total transaction of $254,076.05. Following the acquisition, the chief executive officer now directly owns 269,164 shares in the company, valued at approximately $2,968,878.92. This trade represents a 9.36 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.13% of the company’s stock.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.